FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782117168> ?p ?o ?g. }

• W2782117168 endingPage "1258" @default.
• W2782117168 startingPage "1254" @default.
• W2782117168 abstract "Purpose Stereotactic body radiation therapy (SBRT) is a highly effective and potentially ablative treatment for complex spinal metastases. Recent data have suggested radiobiologic effects of SBRT that expand beyond the traditional concept of DNA damage. Antitumor immunity, vascular damage leading to tumor necrosis, and increased rates of tumor apoptosis have been implied; however, in-human evidence remains scarce. The present study reports unique pathologic confirmation of SBRT-induced biological effects within spinal metastases treated with preoperative SBRT. Methods and Materials Ten patients with spinal metastases secondary to various solid tumors were treated with preoperative single-fraction SBRT (18 Gy) to the magnetic resonance imaging–defined macroscopic metastasis, followed by spinal stabilization within 24 hours. Perioperative samples of spinal metastases were obtained, and 6 patients also had a pre-SBRT biopsy specimen available for a matched comparison. The samples were stained for tumor necrosis on routine hematoxylin-eosin–stained slices and, subsequently, immunohistochemical staining for T cells (CD3+, CD4+, CD8+), natural killer cells (CD56+), endothelium (CD31+), and apoptotic activity (caspase-3). Results Perioperative biopsy specimens were obtained ∼6 hours (range 4.5-7.5) or 21 hours (range 18.5-22.5) after SBRT. Necrosis was observed in 83% of the 21-hour post-SBRT samples (5 of 6) compared with 0% of pre-SBRT biopsies (0 of 6) and 6-hour post-SBRT biopsies (0 of 4). Tumor cell apoptosis had increased greatly in the 21-hour post-SBRT samples compared with before and 6 hours after SBRT. The CD31+ vessel counts decreased after SBRT, as did mitotic activity. Both of the renal cell metastases displayed major decreases in vessel density. Desmoplastic reaction was visible in 67% (4 of 6) of the pre-SBRT samples compared with 100% (10 of 10) the post-SBRT samples. The T-cell and natural killer cell counts were relatively unaffected. Conclusions High-dose single-fraction SBRT induced tumor necrosis, desmoplasia, and tumor apoptosis and decreased tumor vessel density within 24 hours, even in renal cell metastases. The role of immune cells seems limited in this early phase. These first-in-human results imply direct vascular and DNA damage mechanisms important in the clinical efficacy specific to spinal SBRT. Stereotactic body radiation therapy (SBRT) is a highly effective and potentially ablative treatment for complex spinal metastases. Recent data have suggested radiobiologic effects of SBRT that expand beyond the traditional concept of DNA damage. Antitumor immunity, vascular damage leading to tumor necrosis, and increased rates of tumor apoptosis have been implied; however, in-human evidence remains scarce. The present study reports unique pathologic confirmation of SBRT-induced biological effects within spinal metastases treated with preoperative SBRT. Ten patients with spinal metastases secondary to various solid tumors were treated with preoperative single-fraction SBRT (18 Gy) to the magnetic resonance imaging–defined macroscopic metastasis, followed by spinal stabilization within 24 hours. Perioperative samples of spinal metastases were obtained, and 6 patients also had a pre-SBRT biopsy specimen available for a matched comparison. The samples were stained for tumor necrosis on routine hematoxylin-eosin–stained slices and, subsequently, immunohistochemical staining for T cells (CD3+, CD4+, CD8+), natural killer cells (CD56+), endothelium (CD31+), and apoptotic activity (caspase-3). Perioperative biopsy specimens were obtained ∼6 hours (range 4.5-7.5) or 21 hours (range 18.5-22.5) after SBRT. Necrosis was observed in 83% of the 21-hour post-SBRT samples (5 of 6) compared with 0% of pre-SBRT biopsies (0 of 6) and 6-hour post-SBRT biopsies (0 of 4). Tumor cell apoptosis had increased greatly in the 21-hour post-SBRT samples compared with before and 6 hours after SBRT. The CD31+ vessel counts decreased after SBRT, as did mitotic activity. Both of the renal cell metastases displayed major decreases in vessel density. Desmoplastic reaction was visible in 67% (4 of 6) of the pre-SBRT samples compared with 100% (10 of 10) the post-SBRT samples. The T-cell and natural killer cell counts were relatively unaffected. High-dose single-fraction SBRT induced tumor necrosis, desmoplasia, and tumor apoptosis and decreased tumor vessel density within 24 hours, even in renal cell metastases. The role of immune cells seems limited in this early phase. These first-in-human results imply direct vascular and DNA damage mechanisms important in the clinical efficacy specific to spinal SBRT." @default.
• W2782117168 created "2018-01-12" @default.
• W2782117168 creator A5005205765 @default.
• W2782117168 creator A5007967902 @default.
• W2782117168 creator A5015138770 @default.
• W2782117168 creator A5027089510 @default.
• W2782117168 creator A5038655562 @default.
• W2782117168 creator A5043918952 @default.
• W2782117168 creator A5043921084 @default.
• W2782117168 creator A5046498971 @default.
• W2782117168 creator A5064418188 @default.
• W2782117168 creator A5081776505 @default.
• W2782117168 date "2018-04-01" @default.
• W2782117168 modified "2023-09-27" @default.
• W2782117168 title "Early Tissue Effects of Stereotactic Body Radiation Therapy for Spinal Metastases" @default.
• W2782117168 cites W1524125877 @default.
• W2782117168 cites W1534922464 @default.
• W2782117168 cites W1688170978 @default.
• W2782117168 cites W1963798982 @default.
• W2782117168 cites W1966550708 @default.
• W2782117168 cites W1981361272 @default.
• W2782117168 cites W1988138737 @default.
• W2782117168 cites W1997122877 @default.
• W2782117168 cites W2011580181 @default.
• W2782117168 cites W2016811630 @default.
• W2782117168 cites W2029901739 @default.
• W2782117168 cites W2074840874 @default.
• W2782117168 cites W2077814905 @default.
• W2782117168 cites W2093376037 @default.
• W2782117168 cites W2095719154 @default.
• W2782117168 cites W2101608265 @default.
• W2782117168 cites W2111082941 @default.
• W2782117168 cites W2112825838 @default.
• W2782117168 cites W2113701976 @default.
• W2782117168 cites W2129940374 @default.
• W2782117168 cites W2233496256 @default.
• W2782117168 cites W2506991941 @default.
• W2782117168 cites W2591447948 @default.
• W2782117168 cites W2605178884 @default.
• W2782117168 cites W50694536 @default.
• W2782117168 doi "https://doi.org/10.1016/j.ijrobp.2018.01.005" @default.
• W2782117168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29439885" @default.
• W2782117168 hasPublicationYear "2018" @default.
• W2782117168 type Work @default.
• W2782117168 sameAs 2782117168 @default.
• W2782117168 citedByCount "17" @default.
• W2782117168 countsByYear W27821171682018 @default.
• W2782117168 countsByYear W27821171682019 @default.
• W2782117168 countsByYear W27821171682020 @default.
• W2782117168 countsByYear W27821171682021 @default.
• W2782117168 countsByYear W27821171682022 @default.
• W2782117168 countsByYear W27821171682023 @default.
• W2782117168 crossrefType "journal-article" @default.
• W2782117168 hasAuthorship W2782117168A5005205765 @default.
• W2782117168 hasAuthorship W2782117168A5007967902 @default.
• W2782117168 hasAuthorship W2782117168A5015138770 @default.
• W2782117168 hasAuthorship W2782117168A5027089510 @default.
• W2782117168 hasAuthorship W2782117168A5038655562 @default.
• W2782117168 hasAuthorship W2782117168A5043918952 @default.
• W2782117168 hasAuthorship W2782117168A5043921084 @default.
• W2782117168 hasAuthorship W2782117168A5046498971 @default.
• W2782117168 hasAuthorship W2782117168A5064418188 @default.
• W2782117168 hasAuthorship W2782117168A5081776505 @default.
• W2782117168 hasConcept C121608353 @default.
• W2782117168 hasConcept C125473707 @default.
• W2782117168 hasConcept C126322002 @default.
• W2782117168 hasConcept C126838900 @default.
• W2782117168 hasConcept C142724271 @default.
• W2782117168 hasConcept C204232928 @default.
• W2782117168 hasConcept C2775934546 @default.
• W2782117168 hasConcept C2778939058 @default.
• W2782117168 hasConcept C2779013556 @default.
• W2782117168 hasConcept C2780387249 @default.
• W2782117168 hasConcept C2989005 @default.
• W2782117168 hasConcept C503630168 @default.
• W2782117168 hasConcept C509974204 @default.
• W2782117168 hasConcept C71924100 @default.
• W2782117168 hasConceptScore W2782117168C121608353 @default.
• W2782117168 hasConceptScore W2782117168C125473707 @default.
• W2782117168 hasConceptScore W2782117168C126322002 @default.
• W2782117168 hasConceptScore W2782117168C126838900 @default.
• W2782117168 hasConceptScore W2782117168C142724271 @default.
• W2782117168 hasConceptScore W2782117168C204232928 @default.
• W2782117168 hasConceptScore W2782117168C2775934546 @default.
• W2782117168 hasConceptScore W2782117168C2778939058 @default.
• W2782117168 hasConceptScore W2782117168C2779013556 @default.
• W2782117168 hasConceptScore W2782117168C2780387249 @default.
• W2782117168 hasConceptScore W2782117168C2989005 @default.
• W2782117168 hasConceptScore W2782117168C503630168 @default.
• W2782117168 hasConceptScore W2782117168C509974204 @default.
• W2782117168 hasConceptScore W2782117168C71924100 @default.
• W2782117168 hasIssue "5" @default.
• W2782117168 hasLocation W27821171681 @default.
• W2782117168 hasLocation W27821171682 @default.
• W2782117168 hasOpenAccess W2782117168 @default.
• W2782117168 hasPrimaryLocation W27821171681 @default.
• W2782117168 hasRelatedWork W1500628783 @default.
• W2782117168 hasRelatedWork W2017339596 @default.

• next